{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:31:29Z","timestamp":1787308289285,"version":"build-2736575974"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The prevalence of obesity among patients with inflammatory bowel disease (IBD) continues to rise and is associated with adverse IBD outcomes and diminished treatment response. This study reviews the clinical safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with IBD and comorbid obesity and explores their theorized anti-inflammatory mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Published articles through July 2026 were identified via a PubMed search for a narrative review using terms related to GLP-1RA, IBD, safety, effectiveness, and outcomes. Data extraction focused on GLP-1RA intervention details, IBD-related outcomes and inflammatory markers, and proposed anti-inflammatory mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GLP-1RA therapy promotes weight loss in patients with IBD comparable to the general population (about 16 pounds over 18 months). The most frequently reported adverse effects are gastrointestinal, often limiting treatment continuity. Most studies report no significant differences in hospitalization, surgery, steroid use or IBD medication adjustments, and some reported improvement in these outcomes. Data on endoscopic disease activity is limited. Inconsistent effects of GLP-1RA on inflammatory serum biomarkers were noted, with reductions in CRP but no consistent changes in fecal calprotectin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Addressing obesity in patients with IBD is an emerging clinical priority. GLP-1RA therapy demonstrates efficacy in promoting weight loss, improving glycemic control, and reducing systemic inflammation, which may benefit IBD disease activity. Longitudinal studies are required to clarify the long-term impact of GLP-1RA on clinical and endoscopic outcomes in IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1864456","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:16:20Z","timestamp":1787307380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms"],"prefix":"10.3389","volume":"5","author":[{"given":"Shannon","family":"Fernando","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical School, Thomas Jefferson, University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Thomas Jefferson, University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan","family":"Josloff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Thomas Jefferson, University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Zubair","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical School, Thomas Jefferson, University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network","place":["Pittsburgh, PA, United States"]},{"name":"College of Medicine, Drexel University","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina","family":"Shivashankar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Kozuch","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuckoo","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-025-01882-5","article-title":"The \u201cobesity first\u201d approach: Redefining the future of healthcare","volume":"45","author":"Mulder","year":"2026","journal-title":"Indian J Gastroenterol Off J Indian Soc Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/biom15081185","article-title":"Obesity-mediated inflammation and its influence on inflammatory bowel disease: Pathophysiology, clinical impact, and therapeutic implications","volume":"15","author":"Casas-Deza","year":"2025","journal-title":"Biomolecules"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: The linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci AMS"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.sjg_30_21","article-title":"Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD","volume":"27","author":"Johnson","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","unstructured":"Overweight & Obesity Statistics - Niddk"},{"key":"B7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2023.06.036","article-title":"Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: Results of the Constellation Study","volume":"165","author":"Yarur","year":"2023","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","article-title":"Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases","volume":"36","author":"Bassi","year":"2022","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab167","article-title":"Visceral adipose tissue volumetrics inform odds of treatment response and risk of subsequent surgery in IBD patients starting antitumor necrosis factor therapy","volume":"28","author":"Gu","year":"2022","journal-title":"Inflammation Bowel Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/ibd\/izad111","article-title":"Visceral adiposity independently predicts time to flare in inflammatory bowel disease but body mass index does not","volume":"30","author":"Sehgal","year":"2024","journal-title":"Inflammation Bowel Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-021-03968-w","article-title":"Visceral adiposity and inflammatory bowel disease","volume":"36","author":"Rowan","year":"2021","journal-title":"Int J Colorectal Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1016\/j.cgh.2023.01.005","article-title":"Net remission rates with biologic and small molecule treatment in ulcerative colitis: A reappraisal of the clinical trial data","volume":"21","author":"Kayal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/MCG.0b013e318033d71d","article-title":"Mind the gap\u201d: An unmet need for new therapy in IBD","volume":"41","author":"Katz","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13679-023-00506-3","article-title":"GLP-1 receptor agonists in obese patients with inflammatory bowel disease: From molecular mechanisms to clinical considerations and practical recommendations for safe and effective use","volume":"12","author":"Arvanitakis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2026.100272","article-title":"Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy and safety","volume":"18","author":"Jan","year":"2026","journal-title":"Obes Pillars"},{"key":"B16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/ibd\/izae090","article-title":"Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity","volume":"31","author":"Desai","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2024.10305\/2024","article-title":"Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease","volume":"116","author":"Ramos Belinch\u00f3n","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08720-2","article-title":"Efficacy and safety of GLP-1 agonists on metabolic parameters in non-diabetic patients with inflammatory bowel disease","volume":"69","author":"St-Pierre","year":"2024","journal-title":"Dig Dis Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae250","article-title":"GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD","volume":"31","author":"Levine","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.cgh.2024.12.017","article-title":"Safety and clinical effectiveness of GLP1 receptor agonists in inflammatory bowel disease patients","volume":"23","author":"Sehgal","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/apt.70485","article-title":"Systematic review: Efficacy, safety and metabolic outcomes of GLP-1 receptor agonists in inflammatory bowel disease","volume":"63","author":"Maracle","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1186\/s12876-025-04496-5","article-title":"Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"25","author":"Shirmard","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09344-w","article-title":"Glucagon-like peptide-1 receptor agonist therapy does not increase gastrointestinal adverse events in patients with inflammatory bowel disease","volume":"70","author":"Weng","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae276","article-title":"Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease-a Danish nationwide cohort study","volume":"31","author":"Nielsen","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248882","article-title":"Guts, glucose, and gallbladders: The protective role of GLP-1\/GIP receptor agonists against biliary complications in patients with type 2 diabetes and inflammatory bowel disease","volume":"14","author":"Kazi","year":"2025","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(24)01827-4","article-title":"Impact of GLP1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease","author":"Sehgal","year":""},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000057","article-title":"Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity","volume":"20","author":"Lin","year":"2014","journal-title":"Inflammation Bowel Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf301","article-title":"Real-world outcomes of glucagon-like peptide-1 receptor agonist therapy in obese patients with ulcerative colitis and IPAA with a history of pouchitis","volume":"32","author":"Desai","year":"2026","journal-title":"Inflammation Bowel Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103936","article-title":"Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review","volume":"25","author":"Birda","year":"2026","journal-title":"Autoimmun Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04745-0","article-title":"Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: A retrospective cohort study","volume":"399","author":"Aksan","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1621958","article-title":"The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: A systematic review and meta-analysis","volume":"12","author":"Yang","year":"2025","journal-title":"Front Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-58181-y","article-title":"GLP-1 receptor agonists and clinical outcomes in adults with Crohn\u2019s disease and obesity: A propensity score-matched real-world cohort study","author":"Ganju","year":"2026","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: A report from the Epi-IIRN","volume":"19","author":"Gorelik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S1000","DOI":"10.14309\/01.ajg.0001034964.71202.42","article-title":"S1399 safety and effectiveness of glucagon-like peptide 1 receptor agonists for obesity in patients with inflammatory bowel disease","volume":"119","author":"Clarke","year":"2024","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf193","article-title":"Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis","volume":"19","author":"Siranart","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.23937\/2378-3656\/1410281","article-title":"A novel use of liraglutide: Induction of partial remission in ulcerative colitis and ankylosing spondylitis","author":"J","year":""},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01698-z","article-title":"Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives","volume":"392","author":"Zatorski","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2026.101474","article-title":"Glucagon-like peptide-1 receptor agonists across anti-inflammation","volume":"109","author":"Chen","year":"2026","journal-title":"Mol Aspects Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13361","article-title":"The pivotal relation between glucagon-like peptides, NF\u03baB and inflammatory bowel disease","volume":"47","author":"Azmy Nabeh","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/JIR.S152835","article-title":"Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate\/nuclear factor-\u03baB pathway in vitro","volume":"11","author":"Al-Dwairi","year":"2018","journal-title":"J Inflammation Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01734","article-title":"Role of incretin axis in inflammatory bowel disease","volume":"8","author":"Duan","year":"2017","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun","year":"2024","journal-title":"Immunology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner\u2019s glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflammation Bowel Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040383","article-title":"GLP-1 and intestinal diseases","volume":"9","author":"Hunt","year":"2021","journal-title":"Biomedicines"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221879","article-title":"Mechanisms of insulin signaling as a potential therapeutic method in intestinal diseases","volume":"13","author":"Jarmakiewicz-Czaja","year":"2024","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03631-5","article-title":"Protective effect of dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-\u03b2\/PI3K\/NF-\u03baB signaling pathway","volume":"398","author":"Mahdy","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051128","article-title":"GLP-1R agonists and their therapeutic potential in inflammatory bowel disease and other immune-mediated inflammatory diseases, a systematic review of the literature","volume":"13","author":"Thin","year":"2025","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B57","doi-asserted-by":"publisher","first-page":"S994","DOI":"10.14309\/01.ajg.0001034928.98373.b3","article-title":"S1390 outcomes of patients with inflammatory bowel disease on GLP-1 receptor agonists: a propensity score-matched analysis","volume":"119","author":"Khanna","year":"2024","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B59","article-title":"Management of overweight and obesity in patients with inflammatory bowel disease","volume":"20","author":"Shneyderman","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1864456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:16:22Z","timestamp":1787307382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1864456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":59,"alternative-id":["10.3389\/fgstr.2026.1864456"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1864456","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1864456"}}